… in patients hospitalized with COVID-19.[14] Thus, hospitalized COVID-19 patients with high
… potential net clinical benefit of this strategy.[15] [16] [17] Given the unique characteristics of …

… low molecular weight heparin (LMWH) use and mortality in hospitalized COVID-19 patients.
… from two major academic hospitals exclusively for COVID-19 in Wuhan, China, from January …

… for heparin in patients with COVID-19 including direct SARS-CoV-2 antiviral activity of
unfractionated heparin therapy. Its effect could be partially due to this theoretical antiviral activity, …

… for further heparin-based interventions for COVID-19 patients … therapeutic potential of HP as
COVID-19 competitive inhibitors. … facilitate designing of GAG-based COVID-19 therapeutics. …

… Physicians treating patients with COVID-19 are facing novel and unexpected challenges. …
the use of heparins and the correct prevention and diagnosis of VTE in COVID-19 patients, with …

… Various other potential benefits of heparin in COVID-19 have been put forward recently [28]. …
Various other potential benefits of heparin in COVID-19 have been put forward recently [28]. …

… This review considers the potential for heparin and its derivatives to treat inflammatory lung
disease, including COVID-19, ALI, ARDS, cystic fibrosis, asthma, and COPD via the inhaled …

… potential of inhaled nebulised UFH for COVID-19 is awaited. … nebulised UFH in patients
with COVID-19. We have recently … inhaled heparin in hospitalised patients with COVID-19 …

… of LMWH as a potential therapeutic drug for the treatment of COVID-19, paving the way …
COVID-19. With the increasing interest in the use of heparin/LMWH for the treatment of COVID-19…

… molecular weight heparin (LMWH) or unfractionated heparin (… a potential therapy for
coronavirus disease 2019 (COVID-19) … heparins (either LMWH, UFH, or fondaparinux) in …